Shin Yokoyama1,2
Hirokazu Shimizu1,2*†
Akiko Yuno3
Junki Takenaka4,5Naoto Wakabayashi4,6Shiro Watanabe4,6
Ken Kuwahara7Masatake Matsuoka1Tomohiro Onodera1
Norimasa Iwasaki1
Akira Iwata2- 1Department of Orthopedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
- 2Department of Musculoskeletal Oncology, NHO Hokkaido Cancer Center, Sapporo, Japan
- 3Department of Endocrinology and Metabolism, Kin-ikyo Chuo Hospital, Sapporo, Japan
- 4Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
- 5Department of Nuclear Medicine and Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany
- 6Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, Japan
- 7Department of Pathology, NHO Hokkaido Cancer Center, Sapporo, Japan
Background: Tumor-induced osteomalacia (TIO) is a rare disorder characterized by hypophosphatemic osteomalacia, mainly caused by benign tumors with excessive secretion of fibroblast growth factor 23 (FGF23) and somatostatin receptor expression. Although complete excision is recommended, reports on treatment strategies for anatomically challenging surgical cases are lacking. We report an unresectable case of FGF23 transmitted tumor in the cervical vertebrae causing myelopathy, which was treated with surgical decompression combined with radionuclide therapy.
Case presentation: A 52-year-old woman presented to another hospital with complaints of knee pain. After confirming abnormal tracer uptake at the C7 vertebrae using somatostatin receptor scintigraphy and an elevated serum FGF23 level (>800 pg/mL), TIO was diagnosed 7 years after the initial presentation. Gait disturbance occurred 10 years after the initial presentation; therefore, the patient was referred to our department. Magnetic resonance imaging revealed a tumor with spinal cord compression and vertebral artery encasement, making complete resection impossible. Gait disturbance improved after spinal decompression with partial resection of the tumor. Peptide receptor radionuclide therapy targeting somatostatin receptors was initiated 2 years after surgery. Serum phosphate levels normalized, and the tumor size remained stable after the initiation of PRRT. Ambulation was maintained without joint pain recurrence at 3 years after surgery.
Conclusions: The current literature on FGF23 transmitted tumors in the cervical spine includes six cases treated with definitive local therapy. This case suggests an alternative option for unresectable FGF23 transmitted tumor in the vertebrae, causing spinal myelopathy.
1 Introduction
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome attributable to the overproduction of fibroblast growth factor 23 (FGF23) by bone or soft tissue tumors, with an estimated prevalence of 0.43 per 100,000 adults (1). Benign mesenchymal tumors in various regions of the body produce FGF23 and phosphatonins in patients with TIO, leading to hypophosphatemia via reduced renal reabsorption of phosphate and defective bone mineralization, resulting in deformities and pain (1, 2).
Because of the nonspecific nature of the symptoms and small size of the tumor, diagnosing such cases without delay and localizing the tumor are often difficult (3). When detection using conventional modalities fails, somatostatin receptor positron emission tomography/computed tomography, which is a more sensitive tool (pooled detection rate of 87.6%), can be used to identify the tumor causing TIO (4–7).
The first-line treatment for TIO is curative local definitive therapy (8), and alternative therapies include phosphate, active vitamin D, and monoclonal antibodies against FGF23 (1). Recent case reports have suggested peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors as a potentially feasible treatment for FGF23 transmitted tumor (9–11).
Although a few cases of FGF23 transmitted tumor in the cervical spine are available in PubMed, all of them were treated with local definitive therapy (12–16). However, surgical resection of a tumor in the cervical vertebrae is challenging, especially when it compresses the spinal cord and/or vertebral artery. Herein, we report a case of an unresectable FGF23 transmitted tumor causing cervical myelopathy that was treated with spinal decompression and partial resection, followed by PRRT. The patient was ambulatory without joint pain because the findings showed that the tumor size remained stable and serum phosphate levels normalized after the initiation of PRRT. To the best of our knowledge, this is the first report to describe an effective treatment for unresectable FGF23 tumors with cervical cord compression.
2 Case description
A 52-year-old woman presented to a local orthopedic clinic with bilateral knee pain. The pain extended to both the ankles. Blood tests at the age of 54 years revealed hypophosphatemia with a low ratio of the tubular maximum reabsorption of phosphate (TmP) to the glomerular filtration rate (GFR). The patient was subsequently referred to the endocrinology department, where she was diagnosed with hypophosphatemic osteomalacia. Oral phosphate supplementation and active vitamin D analogs were initiated, resulting in partial improvement of knee pain.
Mild symptoms persisted 7 years after the initial presentation. An elevated serum FGF23 level was detected (more than 800 pg/mL, normal range of intact FGF23 by chemiluminescent enzyme immunoassay: 19.9 pg/mL–52.9 pg/mL), although the specific value could not be determined at this time. Because an FGF23 transmitted tumor was suspected, somatostatin receptor scintigraphy and magnetic resonance imaging (MRI) were performed, revealing a solitary lesion with abnormal tracer uptake at the C7 vertebrae (Figure 1). Therefore, TIO was suspected based on the diagnostic criteria (17, 18). Although complete surgical resection is the standard treatment, it poses a high risk of severe nerve injury and functional impairment, rendering it unfeasible. Consequently, conservative therapy, including oral phosphate supplementation and active vitamin D analogs, was continued.
Figure 1. Diagnostic imaging findings. Somatostatin receptor scintigraphy with high sensitivity for diagnosing tumor-induced osteomalacia and detecting a positive lesion found radiotracer uptake in the ventral aspect of the C7–T1 vertebrae (a–c).
Eight years after the diagnosis, anti-FGF23 monoclonal antibody therapy was initiated. However, no improvement in persistent symptoms was observed, and bone scintigraphy revealed increased uptake in multiple areas. Consequently, the therapy was discontinued after 10 months of treatment.
Ten years after the initial diagnosis, the patient was referred to our department with progressive difficulty in ambulating. Among other symptoms, clumsiness dominated the bilateral ring and little fingers, and sensory disturbance involved all four extremities and the trunk. Neurological examinations showed an AISA impairment scale (AIS) Grade C. These findings were consistent with cervical myelopathy at the C8 level. Additional laboratory tests indicated elevated serum FGF23 (13,200 pg/mL), low serum phosphorus, normal serum calcium, elevated intact parathyroid hormone, normal 1,25 dihydroxy vitamin D, and elevated alkaline phosphatase levels. MRI revealed tumor enlargement with intradural extension at the C7-Th1 level, causing circumferential spinal cord compression and vertebral artery involvement (Figures 2A–D).
Figure 2. Longitudinal findings of medical images and laboratory tests. (a, b) Axial T1-weighted and T2-weighted imaging at the time of the diagnosis of tumor-induced osteomalacia (TIO) showing a 37-mm × 26-mm lesion at the right ventral aspect of the C7 vertebra. (c, d) Axial T1-weighted and T2-weighted imaging 10 years after the diagnosis showing a 56-mm × 39-mm lesion and marked tumor enlargement with extension into the spinal canal and compression of the spinal cord. (e, f) Cervical magnetic resonance imaging (MRI) (axial T1-weighted and T2-weighted images) immediately before peptide receptor radionuclide therapy (PRRT) initiation showing a 57-mm × 34-mm residual tumor. (g, h) Cervical MRI (axial T1-weighted and T2-weighted images) One year after PRRT initiation showing a 53-mm × 28-mm lesion. (i) Longitudinal laboratory tests of serum phosphate levels (blue, normal range: 2.5 mg/dL–4.5 mg/dL) and serum calcium levels (orange, normal range 8.5 mg/dL–10.2 mg/dL). Y, year(s).
Therefore, we planned decompression with partial resection. Laminectomy of C6–T1 was performed, and the intradural–extramedullary tumor was partially resected to decompress the spinal cord (Figures 3A, B). Histopathological examination revealed densely proliferating spindle-shaped tumor cells with relatively uniform round nuclei, without mitotic figures or signs of coagulative necrosis. Immunohistochemical analysis was negative for sarcoma-specific markers and positive for CD56 (Figures 3C, D). These histological findings were consistent with those of a phosphaturic mesenchymal tumor (PMT). Based on the diagnostic criteria for TIO (17, 18), this patient was diagnosed with TIO according to the clinical presentation of bone pain without a family history, laboratory findings including hypophosphatemia, low Tmp/GFR ratio, and markedly elevated FGF23 levels, solitary tumor localization confirmed by somatostatin receptor scintigraphy, and histological findings.
Figure 3. Intraoperative findings, gross specimen, and pathological images. (a) Intraoperative image showing partial resection of the intradural–extramedullary tumor compressing the spinal cord followed by laminoplasty. (b) Gross appearance of the resected tumor specimen. (c) Hematoxylin and eosin staining showing spindle-shaped tumor cells with densely proliferating relatively uniform round nuclei without mitotic figures or coagulative necrosis. (d) Immunohistochemical staining for CD56 demonstrating diffuse positive cytoplasmic expression.
One month postoperatively, the patient’s status improved to AIS Grade D, and the patient was discharged with a walking aid. Recovery of gait stability and hand dexterity was noted, supporting a causal relationship between mechanical spinal cord compression by the tumor and the observed myelopathy. Additional local therapy was considered, but external beam radiotherapy was not indicated because the proximity of the tumor to the spinal cord was a limiting factor for treatment.
One year post-surgery, laboratory tests showed increased serum FGF23 levels (23,300 pg/mL). Because the tumor was positive for somatostatin receptor expression, PRRT with 177Lu-dotatate was initiated 2 years postoperatively. Three treatment cycles were administered over a period of several months. MRI revealed stable lesions in the residual tumor (Figures 2E–H). Longitudinal laboratory findings showed that the serum phosphate levels normalized at the follow-up examination 3 years postoperatively (Figure 2I). Serum FGF23 levels were not measured after PRRT initiation due to health insurance-related limitations. The patient remained ambulatory without bone or joint pain recurrence and exhibited stable neurological functions.
3 Discussion and review of the literature
We present a case of an unresectable FGF23 transmitted tumor causing cervical myelopathy that was effectively treated with spinal decompression and partial resection, followed by PRRT. The patient was ambulatory without joint pain 3 years post-surgery; furthermore, the tumor size remained stable, and serum phosphate levels normalized.
This case comprised a tumor at the cervical spine that caused difficulty in walking, and neurological examinations showed cervical myelopathy at the C8 level and AIS Grade C. Because the lesion compressed the vertebral artery and cervical cord, definitive local therapy was infeasible; therefore, decompressive partial resection was performed. Consequently, the patient was discharged with a walking aid, and her status improved to AIS Grade D at 1 month postoperatively. Based on the diagnostic criteria for TIO (17, 18), the patient was diagnosed with TIO according to the clinical presentation of bone pain without a family history; laboratory findings including hypophosphatemia, low Tmp/GFR ratio, and elevated FGF23 levels; solitary tumor localization confirmed by somatostatin receptor scintigraphy; and histological findings compatible with PMT.
While biomedical parameters are often rapidly corrected upon surgical removal of the TIO-causing tumor (1), surgical resection may not always be indicated, as in our case. The findings of our case demonstrated the normalization of serum phosphate levels and stable lesions of the residual tumor after PRRT initiation, suggesting therapeutic efficacy from biochemical and radiological perspectives. Serum FGF23 levels after the initiation of PRRT could not be determined owing to health insurance-related limitations in our country.
We searched MEDLINE for English publications using the following keywords: “FGF23,” “cervical spine,” and “phosphaturic mesenchymal tumor.” Only five cervical FGF23-producing PMTs have been reported in patients aged 52–71 years (Table 1) (12–16). The duration between onset and diagnosis ranged from 1 year to several years. Four patients presented with myelopathy. All patients exhibited hypophosphatemia and high FGF23 levels. Positron emission tomography/computed tomography and MRI enabled the localization of the tumor. Histological examination confirmed PMT and PMT with mixed connective tissue. Four patients underwent total surgical resection, and one patient underwent radiation as local definitive therapy.
Table 1. Reported cases of cervical spine FGF23 transmitted tumor.
Medical management has become the primary treatment for inoperable cases. Conventional therapies include oral phosphate salts and active vitamin D analogs to correct hypophosphatemia (19, 20). Additionally, a monoclonal antibody that directly inhibits FGF23 has been introduced and approved for TIO (20). This antibody blocks the interaction between FGF23 and the fibroblast growth factor receptor 1–Klotho receptor complex, thus restoring phosphate reabsorption and 1,25(OH)2D3 synthesis in the renal proximal tubules (21). Thus, our patient was resistant to conservative therapy.
Most PMTs express somatostatin receptor 2 (22, 23), making PRRT feasible. 177Lu-dotatate binds to somatostatin receptor 2-positive cells, delivering β radiation to induce apoptosis (24). Three case reports have reported clinical or biochemical improvement in unresectable PMTs (9–11). Although limited, these results support PRRT as a promising treatment option for refractory or recurrent diseases. In our case, decompression relieved myelopathy, and PRRT produced radiologically stable status. Cervical PMTs are surgically demanding because of their proximity to vital neurovascular areas; therefore, combining limited resection with decompression radionuclide therapy appears to be a safe and effective strategy. Long-term data are scarce; therefore, continued imaging and biochemical monitoring are essential for these patients.
4 Conclusion
We encountered a rare case of unresectable cervical PMT with myelopathy that was successfully managed using partial decompression and postoperative 177Lu-dotatate therapy. During follow-up, the residual tumor was smaller, the patient was ambulatory, and no biochemical recurrence was observed. This case highlights that treatment comprising both surgical and molecular-targeted therapies can achieve durable control of anatomically unresectable cervical PMTs and is a viable alternative when radical resection and radiotherapy are contraindicated.
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
Ethical approval was not required for the studies involving humans because it is a case report and the informed consent was obtained. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.
Author contributions
SY: Conceptualization, Data curation, Investigation, Writing – original draft, Writing – review & editing, Visualization. HS: Conceptualization, Data curation, Investigation, Writing – original draft, Writing – review & editing, Validation, Visualization. AY: Data curation, Writing – original draft, Writing – review & editing, Validation. JT: Data curation, Validation, Writing – original draft, Writing – review & editing. NW: Data curation, Validation, Writing – original draft, Writing – review & editing. SW: Data curation, Validation, Writing – original draft, Writing – review & editing. KK: Data curation, Investigation, Writing – original draft, Writing – review & editing. MM: Supervision, Validation, Writing – original draft, Writing – review & editing. TO: Supervision, Validation, Writing – original draft, Writing – review & editing. NI: Supervision, Validation, Writing – original draft, Writing – review & editing. AI: Conceptualization, Supervision, Validation, Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was not received for this work and/or its publication.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Hartley IR and Roszko KL. Treatment advances in tumor-induced osteomalacia. Calcif Tissue Int. (2025) 116:24. doi: 10.1007/s00223-024-01317-x
2. Frank FA, Gerber L, Cornelius A, Baumhoer D, and Krieg AH. Fgf-23 transmitted tumor – induced hypophosphatemic osteomalacia: A rare case of a young woman with recurrent fractures and review of the literature. J Bone Oncol. (2022) 33:100413. doi: 10.1016/j.jbo.2022.100413
3. Brandi ML, Clunie GP, Houillier P, Jan de Beur SM, Minisola S, Oheim R, et al. Challenges in the management of tumor-induced osteomalacia (Tio). Bone. (2021) 152:116064. doi: 10.1016/j.bone.2021.116064
4. He Q, Zhang B, Zhang L, Chen Z, Shi X, Yi C, et al. Diagnostic efficiency of 68Ga-DOTANOC PET/CT in patients with suspected tumour-induced osteomalaciaGa. Eur Radiol. (2021) 31:2414–21. doi: 10.1007/s00330-020-07342-2
5. Clifton-Bligh RJ, Hofman MS, Duncan E, Sim I, Darnell D, Clarkson A, et al. Improving diagnosis of tumor-induced osteomalacia with gallium-68 Dotatate pet/Ct. J Clin Endocrinol Metab. (2013) 98:687–94. doi: 10.1210/jc.2012-3642
6. Paquet M, Gauthé M, Zhang Yin J, Nataf V, Bélissant O, Orcel P, et al. Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumoursGa. Eur J Nucl Med Mol Imaging. (2018) 45:1710–20. doi: 10.1007/s00259-018-3971-x
7. Meyer M, Nicod Lalonde M, Testart N, Jreige M, Kamani C, Boughdad S, et al. Detection rate of culprit tumors causing osteomalacia using somatostatin receptor PET/CT: systematic review and meta-analysis. Diagnostics (Basel). (2019) 10:2. doi: 10.3390/diagnostics10010002
8. Arai R, Onodera T, Terkawi MA, Mitsuhashi T, Kondo E, and Iwasaki N. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia. BMC Musculoskelet Disord. (2017) 18:79. doi: 10.1186/s12891-017-1446-z
9. Basu S and Fargose P. 177lu-Dotatate prrt in recurrent skull-base phosphaturic mesenchymal tumor causing osteomalacia: a potential application of prrt beyond neuroendocrine tumors. J Nucl Med Technol. (2016) 44:248–50. doi: 10.2967/jnmt.116.177873
10. Häfliger S, Seidel AK, Schoch E, Reichmann J, Wild D, Steinmann-Schwager S, et al. Peptide receptor radionuclide therapy for a phosphaturic mesenchymal tumor. Case Rep Oncol. (2020) 13:1373–80.
11. Shah R, Lila AR, Jadhav RS, Patil V, Mahajan A, Sonawane S, et al. Tumor induced osteomalacia in head and neck region: Single Center experience and systematic review. Endocr Connect. (2019) 8:1330–53. doi: 10.1530/EC-19-0341
12. Mensah EO, Chalif JI, Baker JG, Chalif E, Biundo J, and Groff MW. Challenges in contemporary spine surgery: A comprehensive review of surgical, technological, and patient-specific issues. J Clin Med. (2024) 13:5460. doi: 10.3390/jcm13185460
13. Akhter M, Sugrue PA, Bains R, and Khavkin YA. Oncogenic osteomalacia of the cervical spine: A rare case of curative resection and reconstruction. J Neurosurg Spine. (2011) 14:453–6. doi: 10.3171/2010.11.SPINE09750
14. Nakamura T, Aizawa T, Hoshikawa T, Ozawa H, Ito N, Fukumoto S, et al. Tumor-induced osteomalacia caused by phosphaturic mesenchymal tumor of the cervical spine. J Orthop Sci. (2015) 20:765–71. doi: 10.1007/s00776-014-0540-4
15. Agarwal N, Kale SS, and Kumari K. Tumor-induced osteomalacia due to a phosphaturic mesenchymal tumor in the cervical spine: a case report and literature review. Neurol India. (2019) 67:1334–40. doi: 10.4103/0028-3886.271274
16. Hockemeyer K, Purswani JM, Kim JK, Givi B, Zan E, Pacione D, et al. Stereotactic body radiation therapy for an unresectable Fgf23-secreting tumor of the cervical spine: A case report and literature review. J Radiosurg SBRT. (2022) 8:321–4.
17. Chen DW, Clines GA, Collins MT, Douyon L, and Choksi PU. A rare cause of atraumatic fractures: case series of four patients with tumor-induced osteomalacia. Clin Diabetes Endocrinol. (2020) 6:12. doi: 10.1186/s40842-020-00101-8
18. Florenzano P, Gafni RI, and Collins MT. Tumor-induced osteomalacia. Bone Rep. (2017) 7:90–7. doi: 10.1016/j.bonr.2017.09.002
19. Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. (2004) 28:1–30. doi: 10.1097/00000478-200401000-00001
20. Fukumoto S. Diagnostic modalities for Fgf23-producing tumors in patients with tumor-induced osteomalacia. Endocrinol Metab (Seoul). (2014) 29:136–43. doi: 10.3803/EnM.2014.29.2.136
21. Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, Högler W, et al. Effect of burosumab compared with conventional therapy on Younger vs Older Children with X-linked hypophosphatemia. J Clin Endocrinol Metab. (2022) 107:e3241–53. doi: 10.1210/clinem/dgac296
22. Fischer A, Kloos S, Maccio U, Friemel J, Remde H, Fassnacht M, et al. Metastatic pheochromocytoma and paraganglioma: somatostatin receptor 2 expression, genetics, and therapeutic responses. J Clin Endocrinol Metab. (2023) 108:2676–85. doi: 10.1210/clinem/dgad166
23. Kim JY, Kim J, Kim YI, Yang DH, Yoo C, Park IJ, et al. Somatostatin receptor 2 (Sstr2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors. Sci Rep. (2024) 14:4047. doi: 10.1038/s41598-024-54599-4
Keywords: cervical myelopathy, FGF23 transmitted tumor, peptide receptor radionuclide therapy, spinal decompression, unresectable case
Citation: Yokoyama S, Shimizu H, Yuno A, Takenaka J, Wakabayashi N, Watanabe S, Kuwahara K, Matsuoka M, Onodera T, Iwasaki N and Iwata A (2026) Spinal decompression and radionuclide therapy for an unresectable FGF23 transmitted tumor causing cervical myelopathy: a case report and literature review. Front. Oncol. 16:1754565. doi: 10.3389/fonc.2026.1754565
Received: 26 November 2025; Accepted: 16 January 2026; Revised: 03 January 2026;
Published: 04 February 2026.
Edited by:
Shinji Miwa, Kanazawa University, JapanReviewed by:
Luciano Colangelo, Sapienza University of Rome, ItalyMathew Most, UMass Memorial Health Care, United States
Copyright © 2026 Yokoyama, Shimizu, Yuno, Takenaka, Wakabayashi, Watanabe, Kuwahara, Matsuoka, Onodera, Iwasaki and Iwata. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hirokazu Shimizu, c2hpbWl6dV9oaXJva2F6dUBuaWZ0eS5jb20=
†ORCID: Hirokazu Shimizu, orcid.org/0000-0002-3997-5900